08 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/07/3110920/0/en/Cogent-Biosciences-Announces-Positive-Top-line-Results-Achieving-Statistical-Significance-Across-All-Primary-and-Key-Secondary-Endpoints-from-the-SUMMIT-Trial-of-Bezuclastinib-in-P.html
07 Jul 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/cogents-phase-3-hits-primary-endpoint-building-case-filing-challenge-blueprints-ayvakit
13 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/13/3008475/0/en/Cogent-Biosciences-Announces-Planned-2025-Milestones-for-Bezuclastinib-and-Emerging-Portfolio-of-Selective-and-Potent-Targeted-Therapeutics.html
05 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/05/2974974/0/en/Cogent-Biosciences-Announces-Bezuclastinib-Presentations-at-the-66th-Annual-American-Society-of-Hematology-ASH-Meeting.html
14 Jun 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/06/14/2898928/0/en/Cogent-Biosciences-Announces-Additional-Clinical-Data-from-Part-1-of-its-Ongoing-SUMMIT-Trial-Evaluating-Bezuclastinib-in-Patients-with-NonAdvanced-Systemic-Mastocytosis-NonAdvSM.html
23 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/23/2887694/0/en/Cogent-Biosciences-Announces-Positive-Updated-Lead-In-Data-from-Ongoing-Phase-3-PEAK-Trial-Evaluating-Bezuclastinib-in-Combination-with-Sunitinib-in-Patients-with-Gastrointestinal-.html